{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T22:46:03Z","timestamp":1767134763287,"version":"build-2238731810"},"update-to":[{"DOI":"10.1002\/14651858.cd003426.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,3,4]],"date-time":"2016-03-04T00:00:00Z","timestamp":1457049600000}}],"reference-count":111,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003426.pub5","type":"journal-article","created":{"date-parts":[[2016,3,6]],"date-time":"2016-03-06T14:15:11Z","timestamp":1457273711000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Drugs for preventing red blood cell dehydration in people with sickle cell disease"],"prefix":"10.1002","author":[{"given":"Srikanth","family":"Nagalla","sequence":"first","affiliation":[{"name":"Thomas Jefferson University; Department of Medicine, Division of Hematology; Medical Center Boulevard 1015 Walnut Street Philadelphia Pennsylvania USA PA 19107-5099"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samir K","family":"Ballas","sequence":"additional","affiliation":[{"name":"Jefferson Medical College, Thomas Jefferson University; Cardeza Foundation for Hematologic Research, Department of Medicine; 1015 Walnut Street Philadelphia USA PA 19107-5099"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,3,4]]},"reference":[{"issue":"8","key":"10.1002\/14651858.CD003426.pub5-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1182\/blood-2007-08-110098","article-title":"Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia","volume":"111","author":"Ataga","year":"2008","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub5-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1365-2141.2010.08520.x","article-title":"Improvements in haemolysis and indicators of erythrocyte survival do not correlate with acute vaso-occlusive crises in patients with sickle cell disease:\u00a0 a phase III randomized, placebo-controlled, double-blind study of the Gardos channel blocker senicapoc (ICA-17043)","volume":"153","author":"Ataga","year":"2011","journal-title":"British Journal of Haematology"},{"issue":"7","key":"10.1002\/14651858.CD003426.pub5-BIB0003|cit3","first-page":"467","article-title":"Efficacy of zinc therapy in prevention of crisis in sickle cell anemia: a double blind, randomized controlled clinical trial","volume":"43","author":"Gupta","year":"1995","journal-title":"Journal of the Association of Physicians of India"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub5-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/00000441-197305000-00002","article-title":"The effect of megestrol acetate on sickling","volume":"265","author":"Adadevoh","year":"1973","journal-title":"American Journal of the Medical Sciences"},{"key":"10.1002\/14651858.CD003426.pub5-BIB0006|cit5","unstructured":"Adams-Graves P Kedar A Koshy M Steinberg M Veith R Ward D Rheothrx (Poloxamer 188) injection for the acute painful episode of sickle cell disease (SCD): a pilot study [abstract] Proceedings of the 30th Annual Meeting of the National Sickle Cell Disease Program; March 1995 1995 118"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub5-BIB0005|cit6","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V90.5.2041","article-title":"RheothRx (Poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study","volume":"90","author":"Adams-Graves","year":"1997","journal-title":"Blood"},{"issue":"Suppl","key":"10.1002\/14651858.CD003426.pub5-BIB0007|cit7","first-page":"410a","article-title":"RheothRx\u00ae (poloxamer 188) injection for the acute painful episode of sickle cell disease","volume":"84","author":"Adams-Graves","year":"1994","journal-title":"Blood"},{"issue":"10 (Suppl 1)","key":"10.1002\/14651858.CD003426.pub5-BIB0008|cit8","first-page":"13a","article-title":"RheothRx (Poloxamer 188) lowers serum LDH during an acute painful episode of sickle cell disease [abstract]","volume":"88","author":"Emanuele","year":"1996","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub5-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1093\/tropej\/fmh097","article-title":"Clinical evaluation of extract of Cajanus cajan (Ciklavit) in sickle cell anaemia","volume":"51","author":"Akinsulie","year":"2005","journal-title":"Journal of Tropical Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub5-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.5144\/0256-4947.1999.97","article-title":"Isoxsuprine in the treatment of sickle cell painful crises: a double-blind comparative study with narcotic analgesia","volume":"19","author":"Al-Jam'a","year":"1999","journal-title":"Annals of Saudi Medicine"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub5-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1159\/000084675","article-title":"Inefficacy of piracetam in the prevention of painful crises in children and adolescents with sickle cell disease","volume":"113","author":"Alvim","year":"2005","journal-title":"Acta Haematologica"},{"key":"10.1002\/14651858.CD003426.pub5-BIB0012|cit12","unstructured":"Ataga KI Orringer EP Styles L Vichinsky E Swerdlow P Davis GA A phase 1B randomized, double-blind, placebo-controlled, single-dose, dose-escalation study of IC 17043 in patients with sickle cell disease (SCD) [abstract] Proceedings of the 30th Annual Meeting of the National Sickle Cell Disease Program 2002 41a"},{"issue":"11 (Part 1 of 2","key":"10.1002\/14651858.CD003426.pub5-BIB0013|cit13","first-page":"454a","article-title":"A phase 1B randomized, double-blind, placebo-controlled, single-dose, dose-escalation study of ICA-17043 in patients with sickle cell disease (SCD) [abstract]","volume":"100","author":"Ataga","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub5-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1046\/j.1365-2141.1996.d01-1744.x","article-title":"Tucaresol increases oxygen affinity and reduces haemolysis in subjects with sickle cell anaemia","volume":"93","author":"Arya","year":"1996","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD003426.pub5-BIB0015|cit15","doi-asserted-by":"crossref","unstructured":"Bartolucci P El Murr T Roudot-Thoraval F Habibi A Santin A Renaud B A randomized, controlled clinical trial of ketoprofen for sickle-cell disease vaso-occlusive crises in adults Blood 2009 3742 7 93124810","DOI":"10.1182\/blood-2009-06-227330"},{"key":"10.1002\/14651858.CD003426.pub5-BIB0016|cit16","unstructured":"Beatty JR Calamaras DM Gamerman SE Nuuhiwa JKB Schmidt NA The effect of guided imagery on pain in children [abstract] Proceedings of the 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA 2007 346"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub5-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/blood.V67.5.1442.1442","article-title":"A collaborative, double-blind randomized study of cetiedil citrate in sickle cell crisis","volume":"67","author":"Benjamin","year":"1986","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD003426.pub5-BIB0018|cit18","first-page":"403","article-title":"Pentoxifylline (Trental) has no significant effect on laboratory parameters in sickle cell disease","volume":"31","author":"Billett","year":"1989","journal-title":"Nouvelle Revue Francaise d'Hematologie"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub5-BIB0019|cit19","first-page":"207","article-title":"Acute painful sickle-cell crises in children: a double-blind, placebo-controlled evaluation of efficacy and safety of cetiedil","volume":"20","author":"Cabannes","year":"1983","journal-title":"Clinical Trials Journal"},{"key":"10.1002\/14651858.CD003426.pub5-BIB0020|cit20","first-page":"199","article-title":"Clinical and biological double-blind-study of Ticlopidine in preventive treatment of sickle cell disease crises","volume":"15","author":"Cabannes","year":"1984","journal-title":"Agents and Actions Supplements"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub5-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0010-7824(97)00156-X","article-title":"Effect of Depo-Provera\u00ae or Microgynon\u00ae on the painful crises of sickle cell anemia patients","volume":"56","author":"Abood","year":"1997","journal-title":"Contraception"},{"issue":"8292","key":"10.1002\/14651858.CD003426.pub5-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0140-6736(82)90320-8","article-title":"Medroxyprogesterone acetate and homozygous sickle cell disease","volume":"2","author":"Ceulaer","year":"1982","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003426.pub5-BIB0023|cit23","unstructured":"De Ceulaer K Gruber C Serjeant G Effect of depo-provera on the haematological and clinical features of homozygous sickle cell disease [abstract] Proceedings of the Commonwealth Caribbean Medical Research Council, 27th Scientific Meeting; 1982 April 14-17; Trinidad and Tobago 1982 47"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub5-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3233\/CH-1990-10104","article-title":"Intravenous oxypentifylline and the painful crisis of sickle cell disease","volume":"10","author":"Ceulaer","year":"1990","journal-title":"Clinical Hemorheology"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub5-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/0021-9681(82)90115-1","article-title":"A double-blind randomized trial of low-dose urea to prevent sickle cell crises","volume":"35","author":"Gail","year":"1982","journal-title":"Journal of Chronic Diseases"},{"key":"10.1002\/14651858.CD003426.pub5-BIB0026|cit26","doi-asserted-by":"crossref","unstructured":"Gladwin MT Kato GJ Weiner D Onyekwere OC Dampier C Hsu L Nitric oxide for inhalation in the acute treatment of sickle cell pain crisis: a randomized controlled trial JAMA 2011 893 902 93124810","DOI":"10.1001\/jama.2011.235"},{"issue":"11","key":"10.1002\/14651858.CD003426.pub5-BIB0027|cit27","first-page":"2824a","article-title":"Assessment of ketoprofen for acute vaso-occlusive crisis in adult patients with sickle cell disease. A randomized double blind monocentric study [abstract]","volume":"102","author":"Godeau","year":"2003","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub5-BIB0029|cit28","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000208633","article-title":"The effect of certain lipid substances on sickling","volume":"45","author":"Isaacs","year":"1971","journal-title":"Acta Haematologica"},{"issue":"7750","key":"10.1002\/14651858.CD003426.pub5-BIB0028|cit29","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S0140-6736(72)90359-5","article-title":"Steroid treatment in the prevention of painful episodes in sickle-cell disease","volume":"1","author":"Isaacs","year":"1972","journal-title":"Lancet"},{"issue":"9088","key":"10.1002\/14651858.CD003426.pub5-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/S0140-6736(97)08462-6","article-title":"Randomised trial of oral morphine for painful episodes of sickle-cell disease in children","volume":"350","author":"Jacobson","year":"1997","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD003426.pub5-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.clpt.2003.10.007","article-title":"Systemic exposure to morphine and the risk of acute chest syndrome in sickle cell disease","volume":"75","author":"Kopesky","year":"2004","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD003426.pub5-BIB0032|cit32","first-page":"213","article-title":"Beneficial effects of Ticlopidine on cardiopulmonary function of sickle cell patients not in crisis","volume":"15","author":"Lonsdorfer","year":"1984","journal-title":"Agents and Actions Supplements"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub5-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2141.1969.tb00391.x","article-title":"A double-blind trial of a phenothiazine compound in the treatment of clinical crisis of sickle cell anaemia","volume":"16","author":"Mahmood","year":"1969","journal-title":"British Journal of Haematology"},{"key":"10.1002\/14651858.CD003426.pub5-BIB0034|cit34","unstructured":"Manion C Parkhurst JB Ogle B Johnson A Edmundson A Aspartame inhibits hypoxia-induced sickling of erythrocytes in patients with sickle cell disease [abstract] Proceedings of the 24th Annual Meeting of the National Sickle Cell Disease Program 2000 172a"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub5-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1067\/mcp.2001.115141","article-title":"Aspartame effect in sickle cell anemia","volume":"69","author":"Manion","year":"2001","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"5&6","key":"10.1002\/14651858.CD003426.pub5-BIB0036|cit36","first-page":"277","article-title":"Placebo controlled double-blind study of pentoxifylline in sickle cell disease patients","volume":"18","author":"Manrique","year":"1987","journal-title":"Journal of Medicine"},{"key":"10.1002\/14651858.CD003426.pub5-BIB0037|cit37","unstructured":"Orringer E Huffman J Johnson A Jones S Whitney J Brockenbrough S A clinical study of the safety, pharmacokinetics and pharmacodynamics of intravenous infusions of 12C79 in sickle cell disease patients not in crisis [abstract] Proceedings of the 16th Annual Meeting of the National Sickle Cell Disease Program; March 1991 1991 112"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003426.pub5-BIB0038|cit38","first-page":"69a","article-title":"Phase 1 study of BW 12C in sickle cell disease (SCD) patients not in crisis [abstract]","volume":"5","author":"Orringer","year":"1988","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003426.pub5-BIB0039|cit39","unstructured":"Orringer EP Binder EA Thomas RP Blythe DS Bustrack JA Schroeder DH Phase I study of 12C79 in sickle cell disease (SCD) patients not in crisis [abstract] Proceedings of the 14th Annual Meeting of the National Sickle Cell Disease Program 1989 57"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub5-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000207105","article-title":"Therapeutic effect of aspirin in sickle cell anaemia","volume":"66","author":"Osamo","year":"1981","journal-title":"Acta Haematologica"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub5-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/S0022-3476(68)80083-6","article-title":"Failure of promazine HCl to prevent the painful episodes in sickle cell anemia","volume":"73","author":"Oski","year":"1968","journal-title":"Journal of Pediatrics"},{"issue":"3","key":"10.1002\/14651858.CD003426.pub5-BIB0042|cit42","first-page":"249","article-title":"Therapeutic effect of diflusinal as prophylaxis in sickle cell anaemia","volume":"24","author":"Oyewo","year":"1987","journal-title":"Clinical Trials Journal"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub5-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/ajh.10321","article-title":"Effects of N-acetylcysteine on dense cell formation in sickle cell disease","volume":"73","author":"Pace","year":"2003","journal-title":"American Journal of Hematology"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub5-BIB0044|cit44","first-page":"834","article-title":"Effectiveness of treatment during osteoarticular pain crises in drepanocytosis; based on the example of pentoxifylline","volume":"80","author":"Pichard","year":"1987","journal-title":"Bulletin de la Societe de Pathologie Exotique et de ses Filiales (Paris)"},{"key":"10.1002\/14651858.CD003426.pub5-BIB0045|cit45","unstructured":"El-Hazmi AF Warsy AS Al-Fawaz I Farid M Refai S Opawoye AD Piracetam in the treatment of sickle cell disease [abstract] Proceedings of the 20th Annual Meeting of the National Sickle Cell Disease Program 1995 162a"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub5-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1159\/000203788","article-title":"Piracetam is useful in the treatment of children with sickle cell disease","volume":"96","author":"El-Hazmi","year":"1996","journal-title":"Acta Haematologica"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub5-BIB0047|cit47","first-page":"22","article-title":"Piracetam for the treatment of sickle cell disease in children - a double blind test","volume":"19","author":"The Piracetam Study Group","year":"1998","journal-title":"Saudi Medical Journal"},{"issue":"8","key":"10.1002\/14651858.CD003426.pub5-BIB0048|cit48","first-page":"608","article-title":"Haemorheological treatment of painful sickle cell crises: use of pentoxifylline","volume":"39","author":"Poflee","year":"1991","journal-title":"Journal of the Association of Physicians India"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub5-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1160\/Th06-12-0718","article-title":"Reduction of painful vaso-occlusive crisis of sickle cell anaemia by tinzaparin in a double-blind randomized trial","volume":"98","author":"Qari","year":"2007","journal-title":"Thrombosis and Haemostasis"},{"issue":"3","key":"10.1002\/14651858.CD003426.pub5-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"238","DOI":"10.2165\/00003088-199222030-00006","article-title":"Prediction of diltiazem plasma concentration curves from limited measurements using compliance data","volume":"22","author":"Rubio","year":"1992","journal-title":"Clinical Pharmacokinetics"},{"key":"10.1002\/14651858.CD003426.pub5-BIB0051|cit51","first-page":"47","article-title":"Scoring system in a pilot effectiveness study of patients with sickle cell anemia","volume":"6","author":"Rubio","year":"1992","journal-title":"Journal of Clinical Research and Pharmacoepidemiology"},{"issue":"3","key":"10.1002\/14651858.CD003426.pub5-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1055\/s-0038-1661088","article-title":"A double-blind trial of Ticlopidine in sickle cell disease","volume":"51","author":"Semple","year":"1984","journal-title":"Thrombosis and Haemostasis"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD003426.pub5-BIB0053|cit53","first-page":"298","article-title":"Hydroxyurea treatment of sickle cell diseases causes megaloblastic transformation of the bone marrow that is responsible for the increase of the mean corpuscular volume [abstract]","volume":"92","author":"Silva-Pinto","year":"2007","journal-title":"Haematologica"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub5-BIB0054|cit54","first-page":"320","article-title":"Double blind randomised clinical trial of pentoxiphyllin in vaso-occlusive sickle cell crisis","volume":"41","author":"Teuscher","year":"1989","journal-title":"Tropical and Geographical Medicine"},{"issue":"9226","key":"10.1002\/14651858.CD003426.pub5-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(00)02508-3","article-title":"Antisickling activity of sodium cromoglicate in sickle-cell disease [letter]","volume":"356","author":"Toppet","year":"2000","journal-title":"Lancet"},{"issue":"9","key":"10.1002\/14651858.CD003426.pub5-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/jama.1974.03230340022022","article-title":"Clinical trials of therapy for sickle cell vaso-occlusive crises","volume":"228","author":"Cooperative Urea Trials Group","year":"1974","journal-title":"Journal of the American Medical Association"},{"issue":"9","key":"10.1002\/14651858.CD003426.pub5-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/jama.1974.03230340027023","article-title":"Treatment of sickle cell crisis with urea in invert sugar. A controlled trial.","volume":"228","author":"Cooperative Urea Trials Group","year":"1974","journal-title":"Journal of the American Medical Association"},{"issue":"9","key":"10.1002\/14651858.CD003426.pub5-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1001\/jama.1974.03230340031024","article-title":"Controlled clinical trials and cooperative study of intravenously administered alkali","volume":"228","author":"Cooperative Urea Trials Group","year":"1974","journal-title":"Journal of the American Medical Association"},{"key":"10.1002\/14651858.CD003426.pub5-BIB0059|cit59","doi-asserted-by":"crossref","unstructured":"Uzun B Kekec Z Gurkan E Efficacy of tramadol vs meperidine in vasoocclusive sickle cell crisis American Journal of Emergency Medicine 2010 445 9 93124810","DOI":"10.1016\/j.ajem.2009.01.016"},{"key":"10.1002\/14651858.CD003426.pub5-BIB0060|cit60","unstructured":"Wallen GR Handel D Mendoza J Chestnut W Nichols J Yates J A randomized pilot study exploring hypnosis as a pain and symptom management strategy in patients with sickle cell disease [abstract] 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007 261"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub5-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1211\/fact.2002.00158","article-title":"Indigenous Nigerian medicinal plants may be useful in the management of sickle-cell disorder","volume":"7","author":"Fonnebo","year":"2002","journal-title":"Focus on Alternative and Complementary Therapies"},{"key":"10.1002\/14651858.CD003426.pub5-BIB0063|cit62","unstructured":"Wambebe C Chemistry and clinical evaluation of NIPRISAN in patients with sickle cell anemia [abstract] Proceedings of the 30th Annual Meeting of the National Sickle Cell Disease Program 2002 46a"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub5-BIB0062|cit63","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1078\/0944-7113-00040","article-title":"Double-blind, placebo-controlled, randomised cross-over clinical trial of Niprisan in patients with sickle cell disorder","volume":"8","author":"Wambebe","year":"2001","journal-title":"Phytomedicine"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub5-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0011-393X(01)80039-4","article-title":"Efficacy of niprisan in the prophylactic management of patients with sickle cell disease","volume":"62","author":"Wambebe","year":"2001","journal-title":"Current Therapeutic Research, Clinical and Experimental"},{"issue":"11 Pt 1","key":"10.1002\/14651858.CD003426.pub5-BIB0065|cit65","first-page":"11a","article-title":"Inhaled nitric oxide for treatment of acute vaso-occlusive crisis in sickle cell disease [abstract]","volume":"100","author":"Weiner","year":"2002","journal-title":"Blood"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD003426.pub5-BIB0066|cit66","first-page":"86A","article-title":"Effectiveness and safety of inhaled nitric oxide for the treatment of vaso-occlusive crisis in pediatric sickle cell disease [abstract]","volume":"51","author":"Weiner","year":"2002","journal-title":"Pediatric Research"},{"issue":"9","key":"10.1002\/14651858.CD003426.pub5-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/jama.289.9.1136","article-title":"Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease","volume":"289","author":"Weiner","year":"2003","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD003426.pub5-BIB0068|cit68","unstructured":"Wynn L Debenham E Faughnan L Martin B Kelly T Reed C Recruitment in the baby hug pediatric hydroxyurea phase 3 clinical trial [abstract] 35th Anniversary Convention of the National Sickle Cell Disease Program; 2007 Sep 17-22; Washington DC, USA. 2007 245"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub5-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1159\/000206360","article-title":"Treatment of sickle cell diseases with aspirin","volume":"72","author":"Zago","year":"1984","journal-title":"Acta Haematologica"},{"issue":"11","key":"10.1002\/14651858.CD003426.pub5-BIB0070|cit70","first-page":"Parts 1 and 2","article-title":"Nitric oxide restores the erythrocyte density of the SAD mouse model of sickle cell disease [abstract]","volume":"96","author":"Adrie","year":"2000","journal-title":"Blood"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub5-BIB0071|cit71","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006111.pub2","article-title":"Piracetam for reducing the incidence of painful sickle cell disease crises","author":"Al Hajeri","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub5-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/ajh.2830320206","article-title":"Effect of hydroxyurea on the rheological properties of sickle erythrocytes in vivo","volume":"32","author":"Ballas","year":"1989","journal-title":"American Journal of Hematology"},{"issue":"11","key":"10.1002\/14651858.CD003426.pub5-BIB0073|cit73","first-page":"Parts 1 and 2","article-title":"Hydration of sickle erythrocytes using a naturally occurring sodium ionophore [abstract]","volume":"96","author":"Ballas","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub5-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1182\/blood.V95.5.1842.005a37_1842_1848","article-title":"Volume control in sickle cells is facilitated by novel anion conductance inhibitor NS1652","volume":"95","author":"Bennekou","year":"2000","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub5-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1182\/blood.V97.5.1451","article-title":"Treatment with NS3623, a novel Cl-conductance blocker, amiliorates erythrocyte dehydration in transgenic SAD mice: a possible new therapeutic approach for sickle cell disease","volume":"97","author":"Bennekou","year":"2001","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD003426.pub5-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1182\/blood.V70.6.1810.1810","article-title":"Inhibition of K transport by divalent cations in sickle erythrocytes","volume":"70","author":"Brugnara","year":"1987","journal-title":"Blood"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub5-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1172\/JCI116597","article-title":"Inhibition of Ca2+activated K + transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives","volume":"92","author":"Brugnara","year":"1993","journal-title":"Journal of Clinical Investigation"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub5-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/00062752-199502020-00005","article-title":"Red cell dehydration in pathophysiology and treatment of sickle cell disease","volume":"2","author":"Brugnara","year":"1995","journal-title":"Current Opinion in Hematology"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub5-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1172\/JCI118537","article-title":"Therapy with oral clotrimazole induces inhibition of the Gardos channel and reduction of erythrocyte dehydration in patients with sickle cell disease","volume":"97","author":"Brugnara","year":"1996","journal-title":"Journal of Clinical Investigation"},{"issue":"20","key":"10.1002\/14651858.CD003426.pub5-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia","volume":"332","author":"Charache","year":"1995","journal-title":"New England Journal of Medicine"},{"issue":"7109","key":"10.1002\/14651858.CD003426.pub5-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1136\/bmj.315.7109.656","article-title":"Management of patients with sickle cell disease","volume":"315","author":"Davies","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub5-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1172\/JCI117149","article-title":"Treatment with oral clotrimazole blocks Ca(2+)-activated K+ transport and reverses erythrocyte dehydration in transgenic SAD mice. A model for therapy of sickle cell disease.","volume":"93","author":"Franceschi","year":"1994","journal-title":"Journal of Clinical Investigation"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub5-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"11","key":"10.1002\/14651858.CD003426.pub5-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1182\/blood.V91.11.4373","article-title":"The efficacy of reducing agents or antioxidants in blocking the formation of dense cells and irreversibly sickled cells in vitro","volume":"91","author":"Gibson","year":"1998","journal-title":"Blood"},{"issue":"2-3","key":"10.1002\/14651858.CD003426.pub5-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0014-5793(00)01930-X","article-title":"Effect of dimethyl adipimidate on K+ transport and shape change in red blood cells from sickle cell patients","volume":"480","author":"Gibson","year":"2000","journal-title":"FEBS Letters"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub5-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1136\/jcp.40.1.99","article-title":"Use of piracetam improves sickle cell deformability in vitro and in vivo","volume":"40","author":"Gini","year":"1987","journal-title":"Journal of Clinical Pathology"},{"key":"10.1002\/14651858.CD003426.pub5-BIB0087|cit87","first-page":"477","article-title":"Red blood cell survival, zinc deficiency and efficacy of zinc therapy in sickle cell disease","volume-title":"Thalassemia: pathophysiology and management, part A","volume":"23","author":"Gupta","year":"1987"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub5-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2141.2007.06884.x","article-title":"Phase I study of magnesium pidolate in combination with hydroxycarbamide for children with sickle cell anaemia.","volume":"140","author":"Hankins","year":"2008","journal-title":"British Journal of Haematology"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub5-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1046\/j.1365-2141.1999.01275.x","article-title":"Mapping the prevalence of sickle cell disease and beta thalassaemia in England: estimating and validating ethnic-specific rates","volume":"104","author":"Hickman","year":"1999","journal-title":"British Journal of Haematology"},{"issue":"7414","key":"10.1002\/14651858.CD003426.pub5-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub5-BIB0091|cit91","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002202","article-title":"Hydroxyurea for sickle cell disease","author":"Jones","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7850","key":"10.1002\/14651858.CD003426.pub5-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0140-6736(74)92518-5","article-title":"Plasma-zinc in sickle cell-anaemia [letter]","volume":"1","author":"Karayalcin","year":"1974","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD003426.pub5-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1542\/peds.84.3.500","article-title":"Mortality in children and adolescents with sickle cell disease","volume":"84","author":"Leikin","year":"1989","journal-title":"Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub5-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1002\/ajh.2830100203","article-title":"Effect of zinc supplementation on serum testosterone level in adult male sickle cell anemia subjects","volume":"10","author":"Prasad","year":"1981","journal-title":"American Journal of Hematology"},{"issue":"3","key":"10.1002\/14651858.CD003426.pub5-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/(SICI)1096-8652(199907)61:3<194::AID-AJH6>3.0.CO;2-C","article-title":"Effect of zinc supplementation on incidence of infections and hospital admissions in sickle cell disease (SCD)","volume":"61","author":"Prasad","year":"1999","journal-title":"American Journal of Hematology"},{"issue":"11 (Pt 1 and 2)","key":"10.1002\/14651858.CD003426.pub5-BIB0096|cit96","article-title":"Decreased exhaled nitric oxide (NO) in patients with sickle cell disease [abstract]","volume":"96","author":"Qureshi","year":"2000","journal-title":"Blood"},{"key":"10.1002\/14651858.CD003426.pub5-BIB0097|cit97","unstructured":"Rivera A Brugnara C Vaso-active molecules modulate Gardos channel activity and hydration state of normal and sickle erythrocytes Blood 2000"},{"issue":"11 (Pt 1 and 2)","key":"10.1002\/14651858.CD003426.pub5-BIB0098|cit98","article-title":"Arginine supplementation of sickle transgenic mice: effects on red cell density and potassium transport [abstract]","volume":"96","author":"Romero","year":"2000","journal-title":"Blood"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub5-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1182\/blood.V99.4.1103","article-title":"Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity","volume":"99","author":"Romero","year":"2002","journal-title":"Blood"},{"issue":"7679","key":"10.1002\/14651858.CD003426.pub5-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/S0140-6736(70)92067-2","article-title":"Oral zinc sulphate in sickle-cell ulcers","volume":"2","author":"Serjeant","year":"1970","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003426.pub5-BIB0101|cit101","volume-title":"Sickle cell disease","author":"Serjeant","year":"1992"},{"issue":"11 (Pt 1 and 2)","key":"10.1002\/14651858.CD003426.pub5-BIB0102|cit102","article-title":"A novel Gardos channel inhibitor, ICA-17043, prevents red blood cell dehydration in vitro and in a mouse model (SAD) of sickle cell disease [abstract]","volume":"96","author":"Stocker","year":"2000","journal-title":"Blood"},{"issue":"6","key":"10.1002\/14651858.CD003426.pub5-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1182\/blood-2002-05-1433","article-title":"ICA-17043, a novel Gardos channel blocker, prevents sickled red blood cell dehydration in vitro and in vivo in SAD mice","volume":"101","author":"Stocker","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub5-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3233\/CH-1988-8524","article-title":"Action of piracetam on cation flux and deformability of sickle cells","volume":"8","author":"Stone","year":"1988","journal-title":"Clinical Hemorheology"},{"issue":"5","key":"10.1002\/14651858.CD003426.pub5-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"535","DOI":"10.3233\/CH-1990-10510","article-title":"Effect of Piracetam on Ca2+-induced K+ efflux from sickle cells","volume":"10","author":"Stuart","year":"1990","journal-title":"Clinical Hemorheology"},{"issue":"2","key":"10.1002\/14651858.CD003426.pub5-BIB0106|cit106","first-page":"203","article-title":"Rheological consequences of sickle-cell dehydration","volume":"12","author":"Stuart","year":"1992","journal-title":"Clinical Hemorheology"},{"key":"10.1002\/14651858.CD003426.pub5-BIB0107|cit107","unstructured":"Zemel B Kawchak D Fung E Ohene-Frempong K Stallings V Zinc supplementation and linear growth in children with sickle cell disease: a pilot study [abstract] Proceedings of the 25th Annual Meting of the National Sickle Cell Disease Program; April 2001; New York 2001 Abst #232"},{"issue":"1","key":"10.1002\/14651858.CD003426.pub5-BIB0108|cit108","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003426.pub3","article-title":"Drugs for preventing red blood cell dehydration in people with sickle cell disease","author":"Nagalla","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD003426.pub5-BIB0109|cit109","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003426.pub4","article-title":"Drugs for preventing red blood cell dehydration in people with sickle cell disease","author":"Nagalla","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub5-BIB0110|cit110","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003426.pub2","article-title":"Drugs for preventing red blood cell dehydration in people with sickle cell disease","author":"Riddington","year":"2002","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD003426.pub5-BIB0111|cit111","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003426.pub2","article-title":"Drugs for preventing red blood cell dehydration in people with sickle cell disease","author":"Singh","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd003426.pub6","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T00:00:00Z","timestamp":1539907200000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD003426.pub5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T16:53:28Z","timestamp":1718384008000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD003426.pub5"}},"subtitle":[],"editor":[{"name":"Cochrane Cystic Fibrosis and Genetic Disorders Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,3,4]]},"references-count":111,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003426.pub5","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,4]]}}}